Relationship between Sustained Disability Progression and Functional System Scores in Relapsing-Remitting Multiple Sclerosis: Analysis of Placebo Data from Four Randomized Clinical Trials

被引:12
作者
Scott, Thomas [1 ]
Wang, Ping [2 ]
You, Xiaojun [2 ]
Mann, Monica [2 ]
Sperling, Bjorn [2 ]
机构
[1] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA
[2] Biogen Idec Inc, Cambridge, MA USA
关键词
Relapsing-remitting multiple sclerosis; Kurtzke scale; Expanded Disability Status Scale; Functional system score; Disability; CONTROLLED PHASE-3; STATUS SCALE; ORAL BG-12; NATALIZUMAB;
D O I
10.1159/000369621
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: The Expanded Disability Status Scale (EDSS), based on different functional system scores (FSS), remains the most frequently used disability assessment in relapsing-remitting multiple sclerosis (RRMS). In this analysis, we evaluated the relationship between sustained disability progression, measured by EDSS, and simultaneous changes in individual FSS domains. Methods: A post hoc analysis was performed on data from placebo-treated RRMS patients from four large, randomized, multicenter, phase 3 clinical trials. Sustained disability progression was defined as a EDSS score increase over a or >= 3- or >= 6-month period. Simultaneous sustained disability progression and worsening of individual FSS domains was analyzed. Results: The majority of patients experienced sustained disability progression and simultaneous worsening of FSS domain, with >= 1-point worsening in the pyramidal domain being most frequently associated with sustained disability progression (in 31-51% of patients), followed by 1-point worsening in the cerebellar (35-41% of patients) and sensory (31-45% of patients) domains. Conclusion: The key FSS components correlating with sustained disability progression, measured by EDSS, appear to be pyramidal, cerebellar, and sensory. In this analysis, the simultaneous worsening of consistent FSS domains confirms the validity and reliability of the use of sustained EDSS progression as a measure of disability progression. (C) 2015 S. Karger AG, Basel
引用
收藏
页码:16 / 23
页数:8
相关论文
共 24 条
[1]  
Coles AJ, 2008, NEW ENGL J MED, V359, P1786, DOI 10.1056/NEJMoa0802670
[2]   Clinical characteristics and long term prognosis in early onset multiple sclerosis [J].
Deryck, Olivier ;
Ketelaer, Pierre ;
Dubois, Benedicte .
JOURNAL OF NEUROLOGY, 2006, 253 (06) :720-723
[3]   Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis [J].
Fox, Robert J. ;
Miller, David H. ;
Phillips, J. Theodore ;
Hutchinson, Michael ;
Havrdova, Eva ;
Kita, Mariko ;
Yang, Minhua ;
Raghupathi, Kartik ;
Novas, Mark ;
Sweetser, Marianne T. ;
Viglietta, Vissia ;
Dawson, Katherine T. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (12) :1087-1097
[4]   Prospective study of multiple sclerosis with early onset [J].
Ghezzi, A ;
Pozzilli, C ;
Liguori, M ;
Marrosu, MG ;
Milani, N ;
Milanese, C ;
Simone, I ;
Zaffaroni, M .
MULTIPLE SCLEROSIS, 2002, 8 (02) :115-118
[5]   Gait analysis in multiple sclerosis: Characterization of temporal-spatial parameters using GAITRite functional ambulation system [J].
Givon, Uri ;
Zeiling, Gabriel ;
Achiron, Anat .
GAIT & POSTURE, 2009, 29 (01) :138-142
[6]   Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis [J].
Gold, Ralf ;
Kappos, Ludwig ;
Arnold, Douglas L. ;
Bar-Or, Amit ;
Giovannoni, Gavin ;
Selmaj, Krzysztof ;
Tornatore, Carlo ;
Sweetser, Marianne T. ;
Yang, Minhua ;
Sheikh, Sarah I. ;
Dawson, Katherine T. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (12) :1098-1107
[7]   Assessment of Definitions of Sustained Disease Progression in Relapsing-Remitting Multiple Sclerosis [J].
Healy, Brian C. ;
Engler, David ;
Glanz, Bonnie ;
Musallam, Alexander ;
Chitnis, Tanuja .
MULTIPLE SCLEROSIS INTERNATIONAL, 2013, 2013
[8]   Change in disability in patients with multiple sclerosis: a 20-year prospective population-based analysis [J].
Hirst, C. ;
Ingram, G. ;
Swingler, R. ;
Compston, D. A. S. ;
Pickersgill, T. ;
Robertson, N. P. .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2008, 79 (10) :1137-1143
[9]   Intramuscular interferon beta-1 alpha for disease progression in relapsing multiple sclerosis [J].
Jacobs, LD ;
Cookfair, DL ;
Rudick, RA ;
Herndon, RM ;
Richert, JR ;
Salazar, AM ;
Fischer, JS ;
Goodkin, DE ;
Granger, CV ;
Simon, JH ;
Alam, JJ ;
Bartoszak, DM ;
Bourdette, DN ;
Braiman, J ;
Brownscheidle, CM ;
Coats, ME ;
Cohan, SL ;
Dougherty, DS ;
Kinkel, RP ;
Mass, MK ;
Munschauer, FE ;
Priore, RL ;
Pullicino, PM ;
Scherokman, BJ ;
WeinstockGuttman, B ;
Whitman, RH ;
Baird, WC ;
Fillmore, M ;
Bona, LM ;
ColonRuiz, ME ;
Nadine, BS ;
Donovan, A ;
Bennett, S ;
Kieffer, YM ;
Umhauer, MA ;
Miller, CE ;
Kilic, AK ;
Sargent, EL ;
Schachter, M ;
Shucard, DW ;
Weider, V ;
Catalano, BA ;
Cervi, JM ;
Czekay, C ;
Farrell, JL ;
Filippini, JS ;
Matyas, RC ;
Michienzi, KE ;
Ito, M ;
OMalley, JA .
ANNALS OF NEUROLOGY, 1996, 39 (03) :285-294
[10]   THE DISABILITY STATUS SCALE FOR MULTIPLE-SCLEROSIS - APOLOGIA PRO DSS SUA [J].
KURTZKE, JF .
NEUROLOGY, 1989, 39 (02) :291-302